Evidence map / Reviewed August 2026
The same word—rapamycin—can refer to an approved medicine, a research tool, or an unproven longevity proposition. This map keeps those categories apart.
Yes. Sirolimus is an immunosuppressant with specific FDA-approved indications, including prevention of organ rejection in certain kidney-transplant patients and treatment of lymphangioleiomyomatosis.
Approval for a specific indication does not establish safety or effectiveness for longevity or general healthspan use.
MedlinePlus drug information ↗Yes. Sirolimus suppresses the immune system. Authoritative patient and prescribing information describes serious risks, important interactions, and circumstances requiring clinical monitoring.
A personalized risk assessment belongs with a qualified clinician who knows the patient and the current prescribing information.
FDA prescribing information ↗Yes. National Institute on Aging materials describe lifespan findings in animal models and the scientific interest in mTOR inhibition.
Animal results are a reason to study a hypothesis. They do not prove a human longevity benefit.
National Institute on Aging ↗Yes. Registered studies are evaluating rapamycin or related mTOR inhibitors in older adults, including safety and biological outcomes.
A study being registered or conducted is not evidence that the intervention works, and results may not yet be available.
ClinicalTrials.gov NCT06658093 ↗That has not been established. Current public evidence does not show that rapamycin extends lifespan in humans.
Claims that a medicine reverses or slows aging should be evaluated especially carefully. Marketing confidence is not clinical evidence.
FDA medication health-fraud guidance ↗A practical reading rule
Those distinctions do not dismiss promising science. They protect the meaning of the science while it develops.
Turn the evidence into better questions →